DHSC faces backlash from CPE over ‘untested’ Drug Tariff changes

The Department of Health and Social Care (DHSC) is pushing ahead with its plans to implement a new drug tariff from April 2024. However, this move has
sparked strong opposition from Community Pharmacy England (CPE), raising concerns about its potential impact on pharmacies and patients.

Earlier, it was announced that the April drug tariff will include the new ‘Retrospective top-up payment for Concessionary prices, which will be applied
automatically for the products listed in Part VIIIE each quarter by the NHS Business Services Authority (NHSBSA), according to the volume the contractor was
paid for.

However, CPE argued that the government has imposed these “untested” changes without their agreement, and strongly opposed them stating that “no recovery or
downward pressure on margin is acceptable given the financial fragility of community pharmacies.”

Janet Morrison, chief executive of CPE, has voiced strong opposition to these changes, arguing that “any system expecting pharmacies to dispense at a loss”
jeopardises the sector’s financial stability and compromises patient care.